查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
抗體藥物偶聯物市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按技術、應用、配銷通路和地理位置
市場調查報告書
商品編碼
1372502

抗體藥物偶聯物市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按技術、應用、配銷通路和地理位置

Antibody Drug Conjugates Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 178 Pages | 訂單完成後即時交付

價格

全球抗體藥物偶聯物市場預計2022年將達到77.93億美元，到2030年將達到296.00億美元；預計2022年至2030年市場年複合成長率為18.2%。

抗體藥物偶聯物的市場成長歸因於開發抗體藥物偶聯物的戰略合作夥伴關係不斷增強、癌症病例發病率上升以及 FDA 對 ADC 的批准增加。然而，ADC 開發和商業化的高成本阻礙了市場的成長。

加強策略夥伴關係開發抗體藥物偶聯物

抗體藥物偶聯物（ADC）在癌症治療方面受到了全世界的廣泛關注。自 2000 年美國食品藥物管理局 (FDA) 批准 Mylotarg（輝瑞的第一個 ADC）以來，儘管發生了 COVID-19 大流行，製藥業領導者的策略決策仍大幅增加。 2020年，多家製藥公司建立了合作夥伴關係來開發ADC。例如，2020年7月，阿斯特捷利康和第一三共合作開發並商業化DS-1062。 DS-1602 是第一三共專有的滋養層細胞表面抗原 2 (TROP2) 導向的 ADC，用於治療多種腫瘤類型。

同樣，2022 年 12 月，默克 (MSD) 與四川科倫藥業股份有限公司子公司科倫生物合作開發七種用於治療癌症的研究性臨床前 ADC。根據協議，默沙東獲得科倫生物科技公司的全球獨家許可，以研究、開發、製造和商業化多種臨床前 ADC 療法。此外，默沙東還擁有為 ADC 候選人獲得額外許可的獨家選項。而對於中國大陸、香港和澳門，科倫生物保留其研究、開發、製造和商業化某些許可和選擇 ADC 的權利。

同樣，2023年4月，BioNTech SE與Duuality Biologics（蘇州）有限公司簽署策略合作協議，開發下一代ADC來治療癌症和自體免疫疾病。根據合作協議，BioNTech SE 將獲得 DualityBio 的主要候選藥物 DB-1303。 DB-1303 是一種基於拓樸異構酶 1 抑制劑的 ADC，針對人類表皮生長因子受體 2 (HER2)。 HER2 是大多數癌症類型中過度表達的共同標靶，有助於癌細胞的侵襲性生長和擴散。其次，BioNTech SE 將獲得另一種基於拓樸異構酶 1 抑制劑的 ADC 候選藥物 DB-1311。公司的目標是在全球範圍內改造和商​​業化創新療法。

抗體藥物偶聯物市場：細分概述

抗體藥物偶聯物市場根據技術、應用、配銷通路和地理位置進行細分。根據技術，抗體藥物偶聯物市場分為可切割接頭和不可切割接頭。 2022年，可切割連接器細分市場佔據了更大的市場佔有率，而不可切割連接器細分市場預計在2022-2030年期間年複合成長率更快。可切割接頭利用化學觸發或其結構的固有特性在腫瘤細胞中釋放細胞毒性有效負載。該技術使用 pH 敏感性、穀胱甘肽敏感性和蛋白酶敏感性機製作為化學觸發因素。可裂解接頭技術廣泛用於開發抗體藥物偶聯物（ADC）。根據 2021 年 3 月發表的文章《抗體-藥物偶聯物：連接基化學的最新進展》，超過 80% 的已批准 ADC 是使用可裂解連接基技術製成的。 Besponsa（inotuzumab ozogamicin）和 Adcetris（brentuximab vedotin）是使用此技術合成的 ADC 的兩個著名範例。這些ADC在釋放親水性無痕有效負載後，在血液循環中長時間保持相對穩定。此外，可切割的接頭可以在細胞內釋放有效負載。

根據應用，抗體藥物偶聯物市場分為血癌、乳癌、卵巢癌、尿路上皮癌等。 2022年，乳癌細分市場佔最大市場佔有率，預計2022-2030年年複合成長率最快，達18.6%。 ADC 的使用顯著改變了乳癌治療的計劃方式。 ADC 的開發有望提高乳癌治療的效力、精確度和安全性。目前，市面上治療三陰性乳癌（TNBC）的商業化產品有Kadcyla/T-DM1（ado-trastuzumab emtansine）、Enhertu/T-DXd（trastuzumab deruxtecan）和Trodelvy/SG（sacituzumab govetican））和轉移性乳癌病例。根據乳癌研究基金會 2023 年 1 月發布的資料，有 17 種 ADC 正在進行臨床試驗。其中 9 個是針對 HER2 的 ADC，正在以不同的有效負載組合進行研究。其餘 8 種 ADC 則正在與新型抗體標靶結合進行研究。

抗體藥物偶聯物市場：地理概述

北美佔據抗體藥物偶聯物市場的最大佔有率。該地區的抗體藥物偶聯物市場分為美國、加拿大和墨西哥。該地區的市場成長歸因於 ADC 研發的增加、產品批准的增加、對 ADC 認知的提高以及營運商之間合併、合作和夥伴關係數量的增加。此外，癌症發生率的顯著上升是導致 ADC 需求增加的其他主要因素之一。

美國是北美乃至全球抗體藥物偶聯物市場的最大貢獻者。美國核准的 ADC 數量最多。到 2021 年 1 月，美國食品藥物管理局 (FDA) 已批准 Mylotarg、Lumoxiti、Adcetris、Kadcyla、Enhertu、Trodelvy、Besponsa、Polivy、Padcev 和 Blenrep 用於多種癌症適應症。此外，美國還有多個 ADC 正在研發中。 ADC 的開發採用了先進的偶聯技術、更有效的有效負載、針對新型抗原和新型接頭等策略。根據 FDA 2021 年 5 月發布的資料，針對 77 種新型 ADC 正在進行 113 項臨床試驗，針對 40 多個不同標靶。預計，不斷增加的 ADC 清單將在未來擴大該國抗體藥物偶聯物的市場規模。

此外，抗體藥物偶聯物市場領導者之間不斷加強的合作關係將擴大他們在不同地區的技術，從而促進市場成長。 2023 年 8 月，ImmunoGen, Inc. 和武田製藥有限公司在日本合作開發和商業化 Immunogen 的 ADC 療法 ELAHERE。根據合作協議，ImmunoGen, Inc. 在獲得 FDA 加速批准 ELAHERE 用於治療鉑類抗藥性卵巢癌後將獲得預付款和額外付款。如果武田透過ELAHERE 在日本的淨銷售額實現某些監管和商業里程碑以及兩位數的特許權使用費，它將向ImmunoGen, Inc.支付額外款項。不過，Immunogen 保留其獨家生產權，並將供應該產品進行開發和銷售。在日本商業化。作為回報，武田將負責所有監管備案，並擁有在日本開發和商業化 ELAHERE 的獨家許可。

在準備美國食品藥物管理局 (FDA)、Cancer.Net、EMA（歐洲藥品管理局）和疾病管制與預防中心 (CDC) 的 ADC 市場報告時提到的一些主要一手和二手來源。

目錄

第 1 章：簡介

  • Insight Partners 研究報告指南
  • 市場區隔

第 2 章：執行摘要

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：抗體藥物偶聯物市場格局

  • 概述
  • PEST分析
    • 全球PEST分析
  • 供應商名單
    • 價值鏈供應商名單

第 5 章：抗體藥物偶聯物市場 - 主要產業動態

  • 主要市場促進因素：
    • 加強策略夥伴關係開發抗體藥物偶聯物
    • 癌症發生率上升
    • FDA 增加對 ADC 的核准
  • 市場限制
    • ADC 開發和商業化成本高昂
  • 市場機會
    • 增加開發 ADC 的投資
  • 市場走向
    • 不斷升級的 ADC 產品線
  • 影響分析：

第 6 章：抗體藥物偶聯物市場 - 全球市場分析

  • 抗體藥物偶聯物市場收入，2017 - 2030

第 7 章：抗體藥物偶聯物市場 - 收入和 2030 年預測 - 按技術

  • 概述
  • 2022 年和 2030 年按技術分類的抗體藥物偶聯物市場收入佔有率 (%)
  • 可切割接頭
  • 不可切割的接頭

第 8 章：抗體藥物偶聯物市場 - 收入和 2030 年預測 -按應用

  • 概述
  • 2022 年及 2030 年抗體藥物偶聯物市場收入佔有率（按應用分類）
  • 血癌
  • 乳癌
  • 卵巢癌
  • 尿路上皮癌
  • 其他

第 9 章：抗體藥物偶聯物市場 - 收入和 2030 年預測 - 按配銷通路

  • 概述
  • 2022 年及 2030 年抗體藥物偶聯物市場收入佔有率，依配銷通路(%)
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 10 章：抗體藥物偶聯物市場 - 區域分析

    • 概述
    • 北美：抗體藥物偶聯物市場（按技術）
    • 北美：抗體藥物偶聯物市場（按應用）
    • 北美：抗體藥物偶聯物市場（按配銷通路）
    • 北美：抗體藥物偶聯物市場（按國家）
      • 美國
      • 加拿大
      • 墨西哥
    • 概述
    • 歐洲：抗體藥物偶聯物市場（按技術）
    • 歐洲：抗體藥物偶聯物市場（依應用）
    • 歐洲：抗體藥物偶聯物市場（按配銷通路）
    • 歐洲：抗體藥物偶聯物市場（依國家）
      • 英國
      • 德國
      • 法國
      • 義大利
      • 西班牙
      • 歐洲其他地區
    • 概述
    • 亞太地區：抗體藥物偶聯物市場（依技術）
    • 亞太地區：抗體藥物偶聯物市場（依應用）
    • 亞太地區：抗體藥物偶聯物市場（按配銷通路）
    • 亞太地區：抗體藥物偶聯物市場（依國家）
      • 中國
      • 日本
      • 印度
      • 韓國
      • 澳洲
      • 亞太地區其他地區
    • 概述
    • 中東和非洲：抗體藥物偶聯物市場（按技術）
    • 中東和非洲：抗體藥物偶聯物市場（按應用）
    • 中東和非洲：抗體藥物偶聯物市場（按配銷通路）
    • 中東和非洲：抗體藥物偶聯物市場（按國家）
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 南非
      • 中東和非洲其他地區
    • 概述
    • 南美洲和中美洲：抗體藥物偶聯物市場（按技術）
    • 南美洲和中美洲：抗體藥物偶聯物市場（按應用）
    • 南美洲和中美洲：抗體藥物偶聯物市場（按配銷通路）
    • 南美洲和中美洲：抗體藥物偶聯物市場（按國家）
      • 巴西
      • 阿根廷
      • 南美洲和中美洲其他地區

第 11 章：抗體藥物偶聯物市場-產業格局

  • 概述
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述
  • 公司製造能力及能力

第 12 章：公司簡介

  • ADC Therapeutics SA
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • ImmunoGen, Inc.
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • RemeGen Co Ltd
  • Takeda Pharmaceutical Co Ltd

第 13 章：附錄

  • 關於我們
  • 專業術語
Product Code: TIPRE00003494

The global antibody drug conjugates market is expected to reach US$ 7.793 billion in 2022 to US$ 29.600 billion by 2030; the market is estimated to record a CAGR of 18.2% from 2022 to 2030.

The market growth of antibody drug conjugates is attributed to growing strategic partnerships to develop antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs. However, high cost of ADCs development and commercialization is hindering the market growth.

Growing Strategic Partnerships to Develop Antibody Drug Conjugates

Antibody-drug conjugates (ADCs) have received significant attention worldwide for cancer therapy. Since the approval of Mylotarg (Pfizer, Inc.'s first ADC) by the US Food and Drug Administration (FDA) in 2000, there has been substantial growth in strategic decisions by pharmaceutical leaders despite the COVID-19 pandemic. In 2020, various pharmaceutical companies entered into partnerships to develop ADCs. For intance, in July 2020, AstraZeneca and Daiichi Sankyo collaborated to develop and commercialize DS-1062. DS-1602 is Daiichi Sankyo's proprietary trophoblast cell-surface antigen 2 (TROP2)-directed ADC to treat multiple tumor types.

Likewise, in December 2022, Merck & Co., Inc. (MSD) and Kelun-Biotech, a Sichuan Kelun Pharmaceutical Co., Ltd. subsidiary, partnered to develop seven investigational preclinical ADCs to treat cancer. Under the agreement, MSD received a grant for exclusive global licenses from Kelun Biotech to research, develop, manufacture, and commercialize multiple investigational preclinical ADC therapies. In addition, MSD has exclusive options to obtain additional licenses for ADC candidates. Whereas for Mainland China, Hing Kong, and Macau, Kelun-Biotech has retained its rights to research, develop, manufacture, and commercialize certain licensed and option ADCs.

Similarly, in April 2023, BioNTech SE and Duality Biologics (Suzhou) Co. Ltd signed a strategic partnership agreement to develop next-generation ADCs to treat cancer and autoimmune diseases. Under the partnership agreement, BioNTech SE will have access to DualityBio's lead candidate, DB-1303. DB-1303 is a topoisomerase-1 inhibitor-based ADC directed against Human Epidermal Growth Factor Receptor 2 (HER2). HER2 is an overexpressed common target in most cancer types and contributes to cancer cells' aggressive growth and spread. Secondly, BioNTech SE will have access to another topoisomerase-1 inhibitor-based ADC candidate, DB-1311. Companies have aimed to transform and commercialize innovative therapies worldwide.

Antibody Drug Conjugates Market: Segmental Overview

The antibody drug conjugates market is segmented on the basis of technology, application, distribution channel, and geography. Based on technology, the antibody drug conjugates market is bifurcated into cleavable linkers and non-cleavable linkers. In 2022, the cleavable linkers segment held a larger market share, and the non-cleavable linkers segment is estimated to register a faster CAGR during 2022-2030. Cleavable linkers use a chemical trigger or inherent properties of their structure to release the cytotoxic payload in the tumor cells. This technology uses pH sensitivity, glutathione sensitivity, and protease sensitivity mechanisms as chemical triggers. The cleavable linker technology is widely used in developing antibody-drug conjugates (ADCs). According to the article "Antibody-drug conjugates: Recent advances in linker chemistry," published in March 2021, over 80% of the approved ADCs are made using cleavable linker technology. Besponsa (inotuzumab ozogamicin) and Adcetris (brentuximab vedotin) are two notable examples of ADCs synthesized using this technology. These ADCs remain comparatively stable for a long time in blood circulation after releasing hydrophilicity traceless payload. Moreover, cleavable linkers can release the payload intracellularly.

Based on application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share, and is estimated to register the fastest CAGR of 18.6% during 2022-2030. The use of ADCs has significantly transformed how breast cancer treatment is planned. The development of ADCs is expected to improve the potency, precision, and safety of breast cancer therapeutics. At present, Kadcyla/T-DM1 (ado-trastuzumab emtansine), Enhertu/T-DXd (trastuzumab deruxtecan), and Trodelvy/SG (sacituzumab govetican) are the commercialized products available in the market to treat triple-negative breast cancer (TNBC) and metastatic breast cancer cases. According to the Breast Cancer Research Foundation data, published in January 2023, 17 ADCs are in clinical trials. 9 out of these are HER2-directed ADCs, which are being studied in different combinations of payloads. The remaining 8 ADCs are being studied in combination with novel antibody targets.

Antibody Drug Conjugates Market: Geographical Overview

North America holds the largest share of the antibody drug conjugates market. The antibody drug conjugates market in this region is split into the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs, rising product approvals, growing awareness about ADCs, and rising number of mergers, collaborations, and partnerships among the operating players. In addition, significantly growing incidences of cancer are among the other leading factors escalating the demand for ADCs.

The US is the largest contributor to the antibody drug conjugates market in North America and the world. The highest numbers of ADCs are approved in the US. By January 2021, the US Food and Drug Administration (FDA) had approved Mylotarg, Lumoxiti, Adcetris, Kadcyla, Enhertu, Trodelvy, Besponsa, Polivy, Padcev, and Blenrep for several cancer indications. In addition, several ADCs are in the pipeline in the US. ADCs have been developed with strategies such as advanced conjugate technologies, more potent payloads, targeting novel antigens, and novel linkers. According to the FDA's data published in May 2021, 113 clinical trials were in studies for 77 novel ADCs that targeted over 40 different targets. The growing list of ADCs in the pipeline is estimated to enhance the antibody drug conjugate market size in the country in the coming future.

In addition, growing partnerships among antibody drug conjugate market leader will expand their technologies in different regions enable market growth. In August 2023, ImmunoGen, Inc. and Takeda Pharmaceutical Company Limited collaborated to develop and commercialize ELAHERE, Immunogen's ADC therapy, in Japan. Under the collaboration agreement, ImmunoGen, Inc. receives upfront and additional payments upon conversion of FDA accelerated approval of ELAHERE to treat platinum-resistant ovarian cancer. If Takeda achieves certain regulatory and commercial milestones and double-digit royalties through the net sales of ELAHERE in Japan, it will pay an additional payment to ImmunoGen, Inc. Nevertheless, Immunogen has retained its exclusive production rights and will supply the product for development and commercialization in Japan. In return, Takeda will be responsible for all regulatory filing and have an exclusive license to develop and commercialize ELAHERE in Japan.

A few of the major primary and secondary sources referred to while preparing the ADC market report on the US Food and Drug Administration (FDA), Cancer.Net, EMA (European Medicines Agency), and Centers for Disease Control and Prevention (CDC).

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the antibody-drug conjugates.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global antibody-drug conjugates, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global antibody-drug conjugates trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Antibody Drug Conjugates Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 Global PEST Analysis
  • 4.3 List of Vendors
    • 4.3.1 List of Vendors in the Value Chain

5. Antibody Drug Conjugates Market - Key Industry Dynamics

  • 5.1 Key Market Drivers:
    • 5.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
    • 5.1.2 Rising Incidences of Cancer Cases
    • 5.1.3 Increasing FDA Approvals for ADCs
  • 5.2 Market Restraints
    • 5.2.1 High Cost of ADCs Development and Commercialization
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Investments to Develop ADCs
  • 5.4 Market Trends
    • 5.4.1 Escalating Pipeline of ADCs
  • 5.5 Impact Analysis:

6. Antibody Drug Conjugates Market - Global Market Analysis

  • 6.1 Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

7. Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology

  • 7.1 Overview
  • 7.2 Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
  • 7.3 Cleavable Linker
    • 7.3.1 Overview
    • 7.3.2 Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Non-cleavable Linker
    • 7.4.1 Overview
    • 7.4.2 Non-cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8. Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application

  • 8.1 Overview
  • 8.2 Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
  • 8.3 Blood Cancer
    • 8.3.1 Overview
    • 8.3.2 Blood Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Breast Cancer
    • 8.4.1 Overview
    • 8.4.2 Breast Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Ovarian Cancer
    • 8.5.1 Overview
    • 8.5.2 Ovarian Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Urothelial Cancer
    • 8.6.1 Overview
    • 8.6.2 Urothelial Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

9. Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel

  • 9.1 Overview
  • 9.2 Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • 9.3 Hospital Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Hospital Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Retail Pharmacies
    • 9.4.1 Overview
    • 9.4.2 Retail Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Online Pharmacies
    • 9.5.1 Overview
    • 9.5.2 Online Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

10. Antibody Drug Conjugates Market - Regional Analysis

  • 10.1 North America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 10.1.1 Overview
    • 10.1.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.1.3 North America: Antibody Drug Conjugates Market, by Technology
    • 10.1.4 North America: Antibody Drug Conjugates Market, by Application
    • 10.1.5 North America: Antibody Drug Conjugates Market, by Distribution Channel
    • 10.1.6 North America: Antibody Drug Conjugates Market, by Country
      • 10.1.6.1 US
        • 10.1.6.1.1 Overview
        • 10.1.6.1.2 US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.1.3 US: Antibody Drug Conjugates Market, by Technology
        • 10.1.6.1.4 US: Antibody Drug Conjugates Market, by Application
        • 10.1.6.1.5 US: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.1.6.2 Canada
        • 10.1.6.2.1 Overview
        • 10.1.6.2.2 Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.2.3 Canada: Antibody Drug Conjugates Market, by Technology
        • 10.1.6.2.4 Canada: Antibody Drug Conjugates Market, by Application
        • 10.1.6.2.5 Canada: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.1.6.3 Mexico
        • 10.1.6.3.1 Overview
        • 10.1.6.3.2 Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.3.3 Mexico: Antibody Drug Conjugates Market, by Technology
        • 10.1.6.3.4 Mexico: Antibody Drug Conjugates Market, by Application
        • 10.1.6.3.5 Mexico: Antibody Drug Conjugates Market, by Distribution Channel
  • 10.2 Europe Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 10.2.1 Overview
    • 10.2.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.2.3 Europe: Antibody Drug Conjugates Market, by Technology
    • 10.2.4 Europe: Antibody Drug Conjugates Market, by Application
    • 10.2.5 Europe: Antibody Drug Conjugates Market, by Distribution Channel
    • 10.2.6 Europe: Antibody Drug Conjugates Market, by Country
      • 10.2.6.1 UK
        • 10.2.6.1.1 Overview
        • 10.2.6.1.2 UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.1.3 UK: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.1.4 UK: Antibody Drug Conjugates Market, by Application
        • 10.2.6.1.5 UK: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.2.6.2 Germany
        • 10.2.6.2.1 Overview
        • 10.2.6.2.2 Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.2.3 Germany: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.2.4 Germany: Antibody Drug Conjugates Market, by Application
        • 10.2.6.2.5 Germany: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.2.6.3 France
        • 10.2.6.3.1 Overview
        • 10.2.6.3.2 France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.3.3 France: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.3.4 France: Antibody Drug Conjugates Market, by Application
        • 10.2.6.3.5 France: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.2.6.4 Italy
        • 10.2.6.4.1 Overview
        • 10.2.6.4.2 Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.4.3 Italy: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.4.4 Italy: Antibody Drug Conjugates Market, by Application
        • 10.2.6.4.5 Italy: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.2.6.5 Spain
        • 10.2.6.5.1 Overview
        • 10.2.6.5.2 Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.5.3 Spain: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.5.4 Spain: Antibody Drug Conjugates Market, by Application
        • 10.2.6.5.5 Spain: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.2.6.6 Rest of Europe
        • 10.2.6.6.1 Overview
        • 10.2.6.6.2 Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.6.3 Rest of Europe: Antibody Drug Conjugates Market, by Technology
        • 10.2.6.6.4 Rest of Europe: Antibody Drug Conjugates Market, by Application
        • 10.2.6.6.5 Rest of Europe: Antibody Drug Conjugates Market, by Distribution Channel
  • 10.3 Asia Pacific Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 10.3.1 Overview
    • 10.3.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.3.3 Asia Pacific: Antibody Drug Conjugates Market, by Technology
    • 10.3.4 Asia Pacific: Antibody Drug Conjugates Market, by Application
    • 10.3.5 Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel
    • 10.3.6 Asia Pacific: Antibody Drug Conjugates Market, by Country
      • 10.3.6.1 China
        • 10.3.6.1.1 Overview
        • 10.3.6.1.2 China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.1.3 China: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.1.4 China: Antibody Drug Conjugates Market, by Application
        • 10.3.6.1.5 China: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.3.6.2 Japan
        • 10.3.6.2.1 Overview
        • 10.3.6.2.2 Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.2.3 Japan: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.2.4 Japan: Antibody Drug Conjugates Market, by Application
        • 10.3.6.2.5 Japan: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.3.6.3 India
        • 10.3.6.3.1 Overview
        • 10.3.6.3.2 India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.3.3 India: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.3.4 India: Antibody Drug Conjugates Market, by Application
        • 10.3.6.3.5 India: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.3.6.4 South Korea
        • 10.3.6.4.1 Overview
        • 10.3.6.4.2 South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.4.3 South Korea: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.4.4 South Korea: Antibody Drug Conjugates Market, by Application
        • 10.3.6.4.5 South Korea: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.3.6.5 Australia
        • 10.3.6.5.1 Overview
        • 10.3.6.5.2 Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.5.3 Australia: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.5.4 Australia: Antibody Drug Conjugates Market, by Application
        • 10.3.6.5.5 Australia: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.3.6.6 Rest of Asia Pacific
        • 10.3.6.6.1 Overview
        • 10.3.6.6.2 Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.6.3 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Technology
        • 10.3.6.6.4 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Application
        • 10.3.6.6.5 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel
  • 10.4 Middle East & Africa Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 10.4.1 Overview
    • 10.4.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.4.3 Middle East & Africa: Antibody Drug Conjugates Market, by Technology
    • 10.4.4 Middle East & Africa: Antibody Drug Conjugates Market, by Application
    • 10.4.5 Middle East & Africa: Antibody Drug Conjugates Market, by Distribution Channel
    • 10.4.6 Middle East & Africa: Antibody Drug Conjugates Market, by Country
      • 10.4.6.1 Saudi Arabia
        • 10.4.6.1.1 Overview
        • 10.4.6.1.2 Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.6.1.3 Saudi Arabia: Antibody Drug Conjugates Market, by Technology
        • 10.4.6.1.4 Saudi Arabia: Antibody Drug Conjugates Market, by Application
        • 10.4.6.1.5 Saudi Arabia: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.4.6.2 UAE
        • 10.4.6.2.1 Overview
        • 10.4.6.2.2 UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.6.2.3 UAE: Antibody Drug Conjugates Market, by Technology
        • 10.4.6.2.4 UAE: Antibody Drug Conjugates Market, by Application
        • 10.4.6.2.5 UAE: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.4.6.3 South Africa
        • 10.4.6.3.1 Overview
        • 10.4.6.3.2 South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.6.3.3 South Africa: Antibody Drug Conjugates Market, by Technology
        • 10.4.6.3.4 South Africa: Antibody Drug Conjugates Market, by Application
        • 10.4.6.3.5 South Africa: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.4.6.4 Rest of Middle East & Africa
        • 10.4.6.4.1 Overview
        • 10.4.6.4.2 Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.6.4.3 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Technology
        • 10.4.6.4.4 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Application
        • 10.4.6.4.5 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Distribution Channel
  • 10.5 South & Central America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 10.5.1 Overview
    • 10.5.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.5.3 South & Central America: Antibody Drug Conjugates Market, by Technology
    • 10.5.4 South & Central America: Antibody Drug Conjugates Market, by Application
    • 10.5.5 South & Central America: Antibody Drug Conjugates Market, by Distribution Channel
    • 10.5.6 South & Central America: Antibody Drug Conjugates Market, by Country
      • 10.5.6.1 Brazil
        • 10.5.6.1.1 Overview
        • 10.5.6.1.2 Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.1.3 Brazil: Antibody Drug Conjugates Market, by Technology
        • 10.5.6.1.4 Brazil: Antibody Drug Conjugates Market, by Application
        • 10.5.6.1.5 Brazil: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.5.6.2 Argentina
        • 10.5.6.2.1 Overview
        • 10.5.6.2.2 Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.2.3 Argentina: Antibody Drug Conjugates Market, by Technology
        • 10.5.6.2.4 Argentina: Antibody Drug Conjugates Market, by Application
        • 10.5.6.2.5 Argentina: Antibody Drug Conjugates Market, by Distribution Channel
      • 10.5.6.3 Rest of South & Central America
        • 10.5.6.3.1 Overview
        • 10.5.6.3.2 Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.3.3 Rest of South & Central America: Antibody Drug Conjugates Market, by Technology
        • 10.5.6.3.4 Rest of South & Central America: Antibody Drug Conjugates Market, by Application
        • 10.5.6.3.5 Rest of South & Central America: Antibody Drug Conjugates Market, by Distribution Channel

11. Antibody Drug Conjugates Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Organic Growth Strategies
    • 11.2.1 Overview
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Companies' Manufacturing Capacities and Capabilities

12. Company Profiles

  • 12.1 ADC Therapeutics SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Pfizer Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 ImmunoGen, Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 GSK Plc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Gilead Sciences Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AstraZeneca Plc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Astellas Pharma Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 RemeGen Co Ltd
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Takeda Pharmaceutical Co Ltd
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Antibody Drug Conjugates Market Segmentation
  • Table 2. List of Vendors
  • Table 3. New Cancer Cases Worldwide, in 2020
  • Table 4. List of FDA-Approved ADCs
  • Table 5. North America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 6. North America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Application
  • Table 7. North America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Distribution Channel
  • Table 8. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 9. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 10. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 11. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 12. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 13. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 14. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 15. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 16. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 17. Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 18. Europe: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Application
  • Table 19. Europe: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Distribution Channel
  • Table 20. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 21. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 22. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 23. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 24. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 25. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 26. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 27. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 28. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 29. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 30. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 31. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 32. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 33. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 34. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 35. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 36. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 37. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 38. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 39. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Application
  • Table 40. Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Distribution Channel
  • Table 41. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 42. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 43. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 44. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 45. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 46. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 47. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 48. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 49. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 50. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 51. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 52. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 53. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 54. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 55. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 56. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 57. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 58. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 59. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 60. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Application
  • Table 61. Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Distribution Channel
  • Table 62. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 63. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 64. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 65. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 66. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 67. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 68. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 69. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 70. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 71. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 72. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 73. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 74. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 75. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Application
  • Table 76. South & Central America: Antibody Drug Conjugates Market Revenue and Forecast To 2030 (US$ Mn) - Distribution Channel
  • Table 77. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 78. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 79. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 80. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 81. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 82. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 83. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 84. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 85. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 86. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
  • Table 87. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
  • Table 88. Glossary of Terms, Antibody Drug Conjugates Market

List Of Figures

  • Figure 1. Antibody Drug Conjugates Market Segmentation, By Region
  • Figure 2. Key Insights
  • Figure 3. Global - PEST Analysis
  • Figure 4. Antibody Drug Conjugates Market - Key Industry Dynamics
  • Figure 5. Impact Analysis of Drivers and Restraints
  • Figure 6. Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
  • Figure 7. Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
  • Figure 8. Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Non-Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 11. Blood Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Breast Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Ovarian Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Urothelial Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • Figure 17. Hospital Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Retail Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Online Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Antibody Drug Conjugates Market, 2022 ($Mn)
  • Figure 21. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. North America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
  • Figure 23. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 25. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 26. Antibody Drug Conjugates Market, 2022 ($Mn)
  • Figure 27. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 28. Europe: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
  • Figure 29. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 30. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 32. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 33. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 34. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 35. Antibody Drug Conjugates Market, 2022 ($Mn)
  • Figure 36. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 37. Asia Pacific: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
  • Figure 38. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 39. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 40. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 41. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 42. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 43. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 44. Antibody Drug Conjugates Market, 2022 ($Mn)
  • Figure 45. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 46. Middle East & Africa: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
  • Figure 47. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 48. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 49. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 50. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 51. Antibody Drug Conjugates Market, 2022 ($Mn)
  • Figure 52. Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 53. South & Central America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
  • Figure 54. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 55. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 56. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)